Table 2.
Cox proportional hazard analysis for risk factors of JAK inhibitor treatment discontinuation due to lack of effectiveness.
| Covariate | Bivariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR [95% CI] | p value | HR [95% CI] | p value | |
| Previous bDMARDs (number) | 1.18 [1.07–1.31] | 0.001 | 1.11 [0.97–1.26] | 0.125 |
| CDAI | 1.03 [1.00–1.05] | 0.023 | 1.02 [0.99–1.05] | 0.121 |
| Previous JAK inhibitors (number) | 1.48 [1.05–2.07] | 0.025 | 1.20 [0.79–1.83] | 0.381 |
| Concomitant GC | 1.68 [0.96–2.94] | 0.072 | 1.43 [0.80–2.56] | 0.223 |
| Concomitant csDMARDs | 0.64 [0.34–1.19] | 0.158 | ||
| RA disease duration (years) | 0.98 [0.96–1.01] | 0.163 | ||
| RF (positivity) | 0.71 [0.42–1.21] | 0.210 | ||
| Age (years) | 0.81 [0.48–1.38] | 0.437 | ||
| Anti-CCP (positivity) | 0.89 [0.48–1.66] | 0.720 | ||
| Sex (female) | 1.08 [0.53–2.21] | 0.826 | ||
HR hazard ratio, CI confidence interval, bDMARDs biologic disease-modifying antirheumatic drugs, CDAI clinical disease activity index, JAK Janus Kinase, GC glucocorticoids, csDMARDs conventional synthetic disease-modifying antirheumatic drugs, RA rheumatoid arthritis, RF rheumatoid factor, anti-CCP anti-cyclic citrullinated peptides.
All covariates that were statistically significant (P < 0.05) or exhibited borderline significance (P < 0.1 and > 0.05) in the bivariate analysis were included in the multivariate analysis.